Introduction
============

Non-alcoholic fatty liver disease (NAFLD), defined as excess accumulation of triglycerides (TGs) in hepatocytes, has become the most common chronic liver condition and is estimated to impact at least 30% of Americans or Chinese ([@B3]; [@B26]; [@B27]). NAFLD can trigger a progressive cascade of liver disorders, ranging from hepatosteatosis to non-alcoholic steatohepatitis, liver cirrhosis, and even hepatocellular carcinoma ([@B6]). Moreover, NAFLD is tightly associated with the development of type 2 diabetes, hypertension, atherosclerosis, and coronary heart disease ([@B18]; [@B5]).

Hepatosteatosis occurs when TG homeostasis is disrupted, due to increased TG synthesis and/or decreased TG clearance. In obesity-associated NAFLD, *de novo* lipogenesis (DNL) is increased, at least in part, by hyperinsulinemia as well as excess availability of carbohydrates ([@B15]). Hepatic lipogenesis is mainly regulated by the transcription factor sterol regulatory element binding transcription protein 1c (*SREBP-1c*), which transcriptionally activates the expression of genes involved in DNL, including fatty acid synthetase (*FASN*), acetyl-CoA carboxylase (*ACC1*), and stearoyl-CoA desaturase-1 (*SCD1*). Indeed, increased hepatic expression levels of *SREBP-1c* and its target genes have been observed in obese rodents and humans ([@B22]; [@B10]).

Stanniocalcins (STC1 and STC2) were initially identified in bony fish as a calcium/phosphate-regulating hormone produced by the corpuscles of Stannius ([@B25]). STC2 has the full-length of stanniocalcin sequence, while STC1 lacks a cysteine residue corresponding to Cys120 of STC2. Subsequent studies revealed that STC2 is ubiquitously expressed and acts as an endocrine, paracrine, or autocrine factor to regulate many biological processes, including tissue remodeling, cell survival, and stress responses ([@B16]; [@B12]; [@B28]). Recently, increasing evidence highlighted its potential role in tumorigenesis, because its expression was markedly upregulated in several types of human malignancy, including stomach, colon, renal, and liver cancers ([@B19]; [@B2]; [@B4]; [@B28]). However, the role of STC2 in the regulation of hepatic TG homeostasis and in the pathogenesis of NAFLD remains unknown.

In the present study, we found that STC2 expression was reduced in the livers of leptin-deficient and high fat diet (HFD) -induced obese mice. Overexpression of STC2 significantly attenuated fatty liver and hypertriglyceridemia in obese mice through activation of the STAT3 signaling pathway. These findings revealed a vital role of STC2 in the regulation of hepatic TG homeostasis and suggested a promising therapeutic target for the related diseases.

Materials and Methods {#s1}
=====================

Animal Experiments
------------------

Male C57BL/6 mice aged 8 weeks were purchased from the Shanghai Laboratory Animal Company (Shanghai, China). *ob/ob* mice were purchased from Nanjing Biomedical Research Institute of Nanjing University (Nanjing, Jiangsu Province, China). HFD-induced obese mice were maintained with free access to HFD (D12492; Research Diet, New Brunswick, NJ, United States) for 12 weeks, and control mice were fed with normal chow diet (NCD) (D12450B; Research Diet). STC2 recombinant protein was purchased from Shanghai Boyi Biotechnology Company (Shanghai, China). For systemic STC2 treatments, *ob/ob* mice received daily intraperitoneal (i.p.) injections of recombinant STC2 protein (0.5 mg/kg). Adenoviruses expressing murine *STC2* gene or green fluorescent protein (GFP) (Ad-STC2 and Ad-GFP) were constructed by Genechem Company (Shanghai, China). Overexpression of *STC2* or GFP in the liver of *ob/ob* mice was achieved by means of tail vein injection of Ad-STC2 or Ad-GFP \[2 × 10^9^ plaque-forming units (pfu) for each mouse\]. All animal experiments were conducted in accordance with the guidelines of Animal Care Committee of Shanghai Jiao Tong University School of Medicine.

Cell Culture
------------

Mouse primary hepatocytes (MPHs) were isolated from adult mice and maintained in hepatocyte medium (Sciencell, Carlsbad, CA, United States). HepG2 cells were cultured in DMEM (Gibco, Gaithersburg, MD, United States) containing 10% fetal bovine serum (FBS; Gibco), 100 IU/mL penicillin, and 100 μg/mL streptomycin. For the *in vitro* model of cellular steatosis, HepG2 cells were exposed to palmitic acid (PA) (200 μM) for 24 h to induce cellular TG accumulation, then were treated with recombinant STC2 protein (20 ng/mL) or vehicle control for another 24 h. To explore the potential signaling pathway affected by STC2, MPHs and HepG2 cells were starved in serum-free DMEM overnight and then treated with recombinant STC2 protein (20 ng/mL) for 1 h. To further investigate the role of STAT3 activation, HepG2 cells were pretreated with S31-201 (50 μM), a STAT3 inhibitor, to block STAT3 function, and then exposed to recombinant STC2 protein or vehicle control for 24 h. Cellular TG contents were extracted and determined using commercial kits (BioVision, Milpitas, CA, United States).

Biochemical Measurements
------------------------

Plasma or hepatic TGs and plasma total cholesterol (TC) were extracted and quantified using commercial kits (BioVision), according to the manufacturer's instructions.

Histological Analysis
---------------------

For Hematoxylin and Eosin (H&E) staining, liver tissues were fixed overnight in 10% formalin, embedded in paraffin, and sectioned at 5 μm. Sections were subjected to standard H&E staining. For Oil Red O staining, liver tissues were fixed overnight in 4% paraformaldehyde, embedded in optimum cutting temperature compound, and cryosectioned. Frozen liver sections were stained with 0.15% Oil Red O according to standard procedures.

RNA Isolation and qRT-PCR
-------------------------

Total RNA was isolated from cell lysates or liver tissues using TRIzol^^®^^ reagent according to the manufacturer's instructions (Invitrogen, Shanghai, China). 2 μg of total RNA was reverse transcribed into cDNA using oligo-dT primers (Promega, Sunnyvale, CA, United States). Quantitative real-time PCR (qRT-PCR) was performed using SYBR^^®^^ Green Premix Ex Taq (Takara, Shiga, Japan) on a Light Cycler 480 (Roche, Basel, Switzerland) to quantify the gene transcripts of interest. The *36B4* gene was used as an internal reference for normalization. The primer sequences are listed in the **Table [1](#T1){ref-type="table"}**.

###### 

Description of primers used in real-time PCR.

  Gene name   Species   Primer sequences (Forward 5′--3′)   Primer sequences (Reverse 5′--3′)
  ----------- --------- ----------------------------------- -----------------------------------
  36B4        Mouse     AGATTCGGGATATGCTGTTGGC              TCGGGTCCTAGACCAGTGTTC
  STC2        Mouse     CTGGGCCAGTTTGTGACCC                 ACGTCATGCAAATCCCATGTAAA
  SREBP-1c    Mouse     CTTTGGCCTCGCTTTTCGG                 TGGGTCCAATTAGAGCCATCTC
  FASN        Mouse     GGCTCTATGGATTACCCAAGC               CCAGTGTTCGTTCCTCGGA
  ACC1        Mouse     AATGAACGTGCAATCCGATTTG              ACTCCACATTTGCGTAATTGTTG
  SCD1        Mouse     TTCTTGCGATACACTCTGGTGC              CGGGATTGAATGTTCTTGTCGT
  PPARα       Mouse     AACATCGAGTGTCGAATATGTGG             CCGAATAGTTCGCCGAAAGAA
  CPT1α       Mouse     TGGCATCATCACTGGTGTGTT               GTCTAGGGTCCGATTGATCTTTG
  ACOX1       Mouse     TAACTTCCTCACTCGAAGCCA               AGTTCCATGACCCATCTCTGTC
  MCAD        Mouse     AACACAACACTCGAAAGCGG                TTCTGCTGTTCCGTCAACTCA
  IL-6        Mouse     AGTTGCCTTCTTGGGACTGA                TCCACGATTTCCCAGAGAAC
  TNF-α       Mouse     AGCCCCCAGTCTGTATCCTT                CTCCCTTTGCAGAACTCAGG
  MCP1        Mouse     AGGTCCCTGTCATGCTTCTG                TCTGGACCCATTCCTTCTTG
  Nrf2        Mouse     TCTTGGAGTAAGTCGAGAAGTGT             GTTGAAACTGAGCGAAAAAGGC
  HO1         Mouse     AAGCCGAGAATGCTGAGTTCA               GCCGTGTAGATATGGTACAAGGA
  α-SMA       Mouse     GTCCCAGACATCAGGGAGTAA               TCGGATACTTCAGCGTCAGGA
  Col4a1      Mouse     CTGGCACAAAAGGGACGAG                 ACGTGGCCGAGAATTTCACC
  Col5a1      Mouse     CTTCGCCGCTACTCCTGTTC                CCCTGAGGGCAAATTGTGAAAA

Western Blots
-------------

Liver tissues and HepG2 cells were lysed in radioimmunoprecipitation (RIPA) buffer containing protease and phosphatase inhibitors (Millipore, Billerica, MA, United States). 50 μg lysates were loaded onto 10% SDS-PAGE and transferred to polyvinylidenedifluoride (PVDF) membranes (Millipore, United States), which were blocked with 10% Bovine Serum Albumin and immunoblotted with antibodies at 4°C overnight. The antibodies used in western blots included, STAT3 (\#12640; 1:1000, \#9145; 1:1000, Cell Signaling Technology, Danvers, MA, United States), AKT (\#13038; 1:1000, \#4821; 1:1000, Cell Signaling Technology), JNK (\#4668; 1:1000, \#9258;1:1000, Cell Signaling Technology), Stanniocalcin 2 (\#A302-369A; 1:500, Bethyl Laboratories, Montgomery, TX, United States), and GAPDH (KC-5G5; 1:5000, Aksomics, Shanghai, China). The proteins were visualized with Immobilon Western Chemiluminescent HRP Substrate (Millipore, United States) according to the manufacturer's protocol.

Insulin Tolerance Tests
-----------------------

*ob/ob* mice were injected i.p. with regular human insulin at a dose of 0.75 IU/kg body weight after fasting for 6 h. Blood glucose levels were monitored at the indicated time points using a portable blood glucose meter (LifeScan, Milpitas, CA, United States).

Statistical Analysis
--------------------

All values are shown as the mean ± standard error of the mean (SEM). Statistical differences were determined by two-tailed Student's *t*-tests. Statistical significances were shown as ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, or ^∗∗∗^*P* \< 0.001.

Results
=======

Hepatic STC2 Expression Was Reduced in Obese Mice
-------------------------------------------------

To determine hepatic STC2 expression in obesity-associated NAFLD, we evaluated its mRNA and protein levels in the livers of *ob/ob* mice. Compared with lean mice, mRNA (**Figure [1A](#F1){ref-type="fig"}**) and protein (**Figure [1B](#F1){ref-type="fig"}**) levels of STC2 were significantly reduced in the livers of *ob/ob* mice. Similarly, the expression of hepatic STC2 was markedly decreased in mice fed a high fat diet (HFD) for 12 weeks as compared with mice fed a normal chow diet (NCD) (**Figures [1C,D](#F1){ref-type="fig"}**). These results indicated that downregulation of STC2 in the liver was a conserved feature of hepatosteatosis in obese mice.

![Hepatic STC2 expression was reduced in obese mice. **(A,B)** Hepatic Stanniocalcin 2 (STC2) mRNA and protein levels, determined by qRT-PCR and western blots, respectively, in *ob/ob* mice aged 8 weeks (*n* = 4--8). **(C,D)** Hepatic STC2 mRNA and protein levels, determined by qRT-PCR and western blots, respectively, in high fat diet (HFD) mice. The 8-week-old mice were fed normal chow diet (NCD) or a HFD for 12 weeks (*n* = 4--6). Data are expressed as the mean ± SEM. ^∗∗∗^*P* \< 0.001.](fphys-09-00873-g001){#F1}

STC2 Alleviated Cellular TG Accumulation Through Suppression of *de Novo* Lipogenesis
-------------------------------------------------------------------------------------

To investigate the role of STC2 in hepatic TG metabolism, HepG2 cells were treated with recombinant STC2 protein or vehicle control. As a result, we found that cellular TG contents were decreased upon STC2 treatment (**Figure [2A](#F2){ref-type="fig"}**). In addition, STC2 dramatically inhibited the palmitate-induced cellular TG deposition (**Figure [2A](#F2){ref-type="fig"}**). To explore the molecular basis for the anti-steatotic effect of STC2, expression levels of genes involved in hepatic TG homeostasis were determined by quantitative real-time PCR. SREBP-1c, a master regulator of *de novo* lipogenesis, was significantly downregulated by STC2 treatment (**Figure [2B](#F2){ref-type="fig"}**). In parallel, expression levels of its downstream target genes, including fatty acid synthetase (*FASN*), acetyl-CoA carboxylase (*ACC1*), and stearoyl-CoA desaturase-1 (*SCD1*), were also reduced (**Figure [2B](#F2){ref-type="fig"}**). However, fatty acid oxidation-related genes, including peroxisome proliferator-activated receptor α (*PPARα*), carnitine palmitoyl transferase 1α (*CPT1α*), medium-chain acyl-CoA dehydrogenase (*MCAD*), and acyl-CoA oxidase (*ACOX1*), were not altered by STC2 treatment (**Figure [2C](#F2){ref-type="fig"}**).

![STC2 alleviated hepatic TG accumulation through suppression of *de novo* lipogenesis. **(A)** Cellular triglyceride (TG) contents in HepG2 cells. Cells were treated with recombinant STC2 protein (20 ng/mL) or phosphate-buffered saline (PBS) as a vehicle control for 24 h, with or without preincubated with palmitic acid (PA; 200 μM) for 24 h. **(B)** The mRNA levels of *SREBP-1c*, *FASN*, *ACC1*, and *SCD1* in HepG2 cells were measured. Cells were exposed to PA (200 μM) for 24 h, then were treated with recombinant STC2 protein (20 ng/mL) or vehicle control (PBS) for another 24 h. **(C)** The mRNA levels of *PPARα*, *ACOX1*, *MCAD*, and *CPT1α* in HepG2 were measured as in **(B)**. Data are expressed as the mean ± SEM. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001.](fphys-09-00873-g002){#F2}

STC2 Activated the STAT3 Signaling Pathway to Alleviate Hepatosteatosis
-----------------------------------------------------------------------

We analyzed the potential mechanism by which STC2 suppressed lipogenesis and alleviated TG accumulation in hepatocytes. We found that STC2 treatment resulted in marked activation of the STAT3 signaling pathway, as shown by enhanced phosphorylated STAT3, while the AKT and JNK pathways were unaffected (**Figures [3A,B](#F3){ref-type="fig"}**). To determine whether STAT3 activation was indispensable for the anti-steatotic effects of STC2, S31-201, a STAT3 inhibitor, was used to block STAT3 function. Our data showed that S31-201 abrogated the effects of STC2 on TG contents and lipogenic gene expression (**Figures [3C,D](#F3){ref-type="fig"}**).

![STC2 activated the STAT3 signaling pathway to alleviate hepatosteatosis. **(A,B)** Phosphorylated and total STAT3, AKT, and JNK in HepG2 cells **(A)** and MPHs **(B)** incubated with PBS or STC2 (20 ng/mL) protein for 1 h. Total STAT3, AKT, and JNK were used as loading controls. **(C)** Cellular TG contents in HepG2. Cells were treated with recombinant STC2 protein (20 ng/mL) or PBS vehicle control for 24 h, with or without preincubation with S31-201 (50 μM), a STAT3 inhibitor, for 2 h. **(D)** The mRNA levels of *SREBP-1c* and its target genes in HepG2 cells were measured as in **(C)**. Data are expressed as the mean ± SEM. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001.](fphys-09-00873-g003){#F3}

Systemic STC2 Treatment Ameliorated Hepatosteatosis in Obese Mice
-----------------------------------------------------------------

To elucidate the function of STC2 *in vivo*, *ob/ob* mice were injected i.p. with recombinant STC2 protein (0.5 mg/kg) once daily. A drastic decrease in hepatic TG contents (**Figure [4A](#F4){ref-type="fig"}**) and liver weight (**Figure [4B](#F4){ref-type="fig"}**) were observed in STC2-treated mice. Systemic STC2 administration also decreased the balloon cells and neutral lipid deposition in the livers of *ob/ob* mice as assessed by H&E and Oil Red O staining (**Figure [4C](#F4){ref-type="fig"}**). Plasma TG and total cholesterol (TC) levels were markedly reduced (**Figures [4D,E](#F4){ref-type="fig"}**). In parallel, STC2 partially ameliorated the inflammation, oxidative stress and fibrosis characteristics of *ob/ob* mice (**Supplementary Figures [S1A--C](#SM1){ref-type="supplementary-material"}**). Plasma ALT and AST levels were also significantly decreased in STC2-treated mice (**Supplementary Figures [S1D,E](#SM1){ref-type="supplementary-material"}**). In addition, fasting blood glucose levels and insulin sensitivity were dramatically improved upon STC2 treatment (**Figures [4F,G](#F4){ref-type="fig"}**). Consistently, STC2 also activated the STAT3 pathway and reduced the expression of SREBP-1c and its target genes in the liver (**Figures [4H,I](#F4){ref-type="fig"}**).

![Systemic STC2 treatment ameliorated hepatosteatosis in obese mice. **(A,B)** Liver TG contents **(A)** and liver weight **(B)** in *ob/ob* mice intraperitoneally injected with recombinant STC2 protein (0.5 mg/kg) or vehicle control for 9 days (*n* = 7--8). **(C)** Representative histology (H&E, left) or Oil Red O (right) staining showing TG accumulation in livers from mice injected with STC2 protein versus vehicle control. Original magnification, 200×. **(D,E)** Plasm TG **(D)** and plasm TC **(E)** levels in mice. **(F,G)** Fasting blood glucose **(F)** and insulin tolerance test results **(G)** in mice. **(H)** Phosphorylated and total STAT3 in the livers of mice. Total STAT3 were used as loading controls. **(I)** The mRNA levels of hepatic *SREBP-1c* and its target genes in mice. Data are expressed as the mean ± SEM. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001. H&E, Hematoxylin & Eosin; TG, triglyceride; TC, total cholesterol.](fphys-09-00873-g004){#F4}

Hepatic STC2 Overexpression Attenuated Fatty Livers in *ob/ob* Mice
-------------------------------------------------------------------

Next, *STC2* gene was overexpressed in the livers of *ob/ob* mice by delivering an adenovirus via tail vein injection. Increased mRNA and protein levels of STC2 in the liver were confirmed by qRT-PCR and western blots, respectively, while its expression in white adipose tissues were not affected (**Figure [5A](#F5){ref-type="fig"}** and **Supplementary Figures [S2A,B](#SM2){ref-type="supplementary-material"}**). Hepatic overexpression of STC2 significantly decreased liver TG content (**Figure [5B](#F5){ref-type="fig"}**) and liver weight (**Figure [5C](#F5){ref-type="fig"}**). Plasma TG levels were markedly reduced (**Figure [5D](#F5){ref-type="fig"}**), and a declining tendency in plasma TC levels was also observed (**Figure [5E](#F5){ref-type="fig"}**). Consistently, hepatic overexpression of STC2 partially ameliorated the inflammation, oxidative stress and fibrosis characteristics of *ob/ob* mice (**Supplementary Figures [S2C--E](#SM2){ref-type="supplementary-material"}**). Plasma ALT levels were significantly reduced, while AST levels were not affected in STC2-overexpressed *ob/ob* mice (**Supplementary Figures [S2F,G](#SM2){ref-type="supplementary-material"}**). In addition, fasting hyperglycemia and insulin resistance were improved by STC2 overexpression in *ob/ob* mice (**Figures [5F,G](#F5){ref-type="fig"}**). At the molecular level, overexpression of STC2 also induced hepatic STAT3 activation and reduced the expression of *de novo* lipogenesis related genes (**Figures [5H,I](#F5){ref-type="fig"}**).

![Hepatic STC2 overexpression attenuated fatty liver in *ob/ob* mice. **(A)** The mRNA and protein levels of STC2 in *ob/ob* mice injected with adenovirus containing GFP or the STC2 gene (*n* = 7--8). **(B,C)** Liver TG contents **(B)** and liver weights **(C)** in mice. **(D,E)** Plasm TG **(D)** and plasm TC **(E)** levels in mice. **(F,G)** Fasting blood glucose **(F)** and insulin tolerance test results **(G)** in mice. **(H)** Phosphorylated and total STAT3 in the livers of mice. Total STAT3 were used as loading controls. **(I)** The mRNA expressions of hepatic *SREBP-1c* and its target genes in mice. Data are expressed as the mean ± SEM. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001. TG, triglyceride; TC, total cholesterol.](fphys-09-00873-g005){#F5}

Discussion
==========

Previous studies have shown that STC2 regulates many biological processes, including tissue remodeling, cell survival, stress responses, and tumorigenesis. However, little is known about its function in metabolic homeostasis. Interestingly, STC2 knockout mice were reported to present with deregulated glycemia when they were fed with a hypercaloric diet ([@B17]). Enhanced glucagon immunostaining in the islet cells and elevated circulating glucagon levels were observed in STC2-null mice ([@B17]).

In the present study, we identified a novel role of STC2 in the regulation of hepatic TG homeostasis. Systemic STC2 administration or liver-specific overexpression of STC2 significantly ameliorated TG accumulation in obese mice. At the molecular level, it has been shown that STC2 can modulate multiple signaling pathways, such as PI3K/AKT, ERK1/2, in tumor cells and osteoblast ([@B31]; [@B30]). However, our data showed that the AKT and JNK pathways were unaffected in STC2-treated hepatocytes. Therefore, the role and downstream signaling pathways of STC2 might be tissue or cell-specific, which needs further investigations in future studies.

In addition, studies using genetically engineered mice have shown the significance of the STAT3 signaling pathway in the pathophysiology of fatty liver. The anti-steatotic effects of STAT3 were mediated, at least in part, via transcriptional suppression of SREBP-1c and subsequent repression of hepatic *de novo* lipogenesis ([@B24]). As a result, disruption of STAT3 or its upstream molecule gp130 in hepatocytes exacerbated fatty liver induced by a high fat diet ([@B11]), alcohol-containing diet ([@B9]), or a choline deficient ethionine-supplemented diet ([@B14]). Overexpression of constitutively activated *STAT3* attenuated high fat diet-induced fatty livers ([@B11]). Consistently, genetic variants in *STAT3* were associated with non-alcoholic fatty liver disease in humans ([@B23]). Furthermore, several cytokines are known to activate the STAT3 pathway to regulate hepatic TG homeostasis. For instance, treatment with IL-6 ameliorated fatty liver by inducing STAT3 phosphorylation in *ob/ob* and HFD- induced obese mice ([@B8]), while deletion of IL-6 or hepatic STAT3 resulted in steatosis and hepatocellular damage in IL-10 knockout mice ([@B20]). In addition, IL-22 ameliorated non-alcoholic and alcoholic fatty livers through activation of the STAT3 pathway in hepatocytes ([@B13]; [@B29]). Here, in our studies we found that plasma IL-22 contents were reduced by STC2 treatment or overexpression (**Supplementary Figures [S3A,B](#SM3){ref-type="supplementary-material"}**). Previous studies have shown that inflammatory signaling, including NF-κB and AP-1/JunD, are involved in IL-22 production ([@B21]; [@B1]; [@B7]). Since STC2 treatment can reduce hepatic inflammation in obese mice, we speculate that reduction of IL-22 in STC-2 treated mice might be attributed to decreased inflammation.

Conclusion
==========

Our findings demonstrated that STC2 was an important metabolic regulator in the liver. STC2 ameliorated hepatosteatosis and hypertriglyceridemia in obese mice, mainly through activation of the STAT3 signaling pathway. Thus, STC2 may be a promising therapeutic target for fatty liver and dyslipidemia.
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###### 

Systemic STC2 treatment ameliorated hepatosteatosis in obese mice. **(A)** Relative mRNA levels of IL-6, TNF-α, MCP1 in the livers of two groups. **(B)** Relative mRNA levels of Nrf2, HO1 in the livers of two groups. **(C)** Relative mRNA levels of hepatic α-SMA, Col4a1, Col5a1in two groups. **(D,E)** Plasma ALT and AST levels in two groups. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001. MCP1, Chemokine (C-C motif) ligand 2 (CCL2); Nrf2, nuclear factor, erythroid derived 2, like 2; HO1, heme oxygenase 1; Col4a1, collagen, type IV, alpha 1; Col5a1, collagen, type V, alpha 1.

###### 

Click here for additional data file.

###### 

Hepatic STC2 overexpression attenuated fatty liver in ob/ob mice. **(A,B)** Relative mRNA and protein expression of STC2 in white adipose tissues. **(C)** Relative mRNA levels of IL-6, TNF-α, MCP1 in the livers of two groups. **(D)** Relative mRNA levels of Nrf2, HO1 in the livers of two groups. **(E)** Relative mRNA levels of hepatic α-SMA, Col4a1, Col5a1 in two groups. **(F,G)** Plasma ALT and AST levels in two groups. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001.

###### 

Click here for additional data file.

###### 

Plasma IL-22 contents in systemic STC2-treated and hepatic STC2 overexpressed ob/ob mice. **(A,B)** Plasma IL-22 contents in STC2-treated ob/ob mice **(A)** or hepatic STC2 overexpressed ob/ob mice **(B)** by ELISA kit. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001.

###### 

Click here for additional data file.
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